Skip to main content
. 2017 Jan 24;61(2):e01701-16. doi: 10.1128/AAC.01701-16

TABLE 1.

Baseline characteristics of children with TB with and without HIV coinfection

Characteristic Value for group
P value
All (n = 113) TB (n = 54) TB/HIV (n = 59)
Median (IQR) age, yr 5.0 (2.2–8.3) 4.8 (2.0–8.3) 5.0 (2.9–8.9) 0.642
No. (%) with age, yr 0.822
    <2 24 (21.2) 12 (22.2) 12 (20.3)
    ≥2 89 (78.8) 42 (77.8) 47 (79.7)
No. (%) with age, yr 0.708
    <5 54 (47.8) 27 (50.0) 27 (45.8)
    ≥5 59 (52.2) 27 (50.0) 32 (54.2)
No. (%) male 63 (55.8) 32 (59.3) 31 (52.5) 0.570
Median (IQR) body wt, kg 14.0 (8.8–19.5) 14.1 (8.8–21.8) 14.0 (8.5–19.0) 0.406
Median (IQR) height, cm 99.0 (82.0–119.0) 99.0 (82.0–122.0) 98.0 (82.0–117.0) 0.553
Nutritional status
    Median (IQR) wt-for-age Z scorea −2.5 (−3.8 to −1.4) −2.1 (−3.1 to −0.9) −2.7 (−4.0 to −2.0) 0.023
    Median (IQR) height-for-age Z score −2.0 (−3.2 to −1.1) −1.6 (−2.4 to −0.6) −2.8 (−3.9 to −1.8) <0.001
    Median (IQR) BMI-for-age Z score −1.8 (−2.9 to −0.5) −1.4 (−2.9 to −0.6) −2.0 (−3.4 to −0.4) 0.547
    Median (IQR) midarm circumference, cm 14.0 (12.0–16.0) 14 (13.0–16.5) 13 (11.2–15.5) 0.131
    Median (IQR) head circumference, cm 48.0 (46.0–50.0) 48.0 (46.0–51.0) 48 (45.0–49.0) 0.143
Median (IQR) drug dose, mg/kg
    Isoniazid 11.2 (9.1–12.8) 11.4 (9.5–12.8) 10.4 (9.0–12.9) 0.314
    Rifampin 15.8 (13.6–18.8) 16.7 (14.2–18.8) 15.2 (13.5–18.8) 0.262
    Pyrazinamide 24.8 (22.6–30.0) 26.5 (23.5–32.3) 24.7 (22.3–29.0) 0.228
    Ethambutol 16.9 (15.0–20.6) 18.0 (15.8–22.7) 16.5 (14.9–19.4) 0.167
No. (%) with TB disease classification: <0.001
    Pulmonary 85 (75.2) 29 (52.8) 56 (94.9)
    Extrapulmonary 28 (24.8) 25 (47.2) 3 (5.1)
No. (%) with outcome: 0.513
    Completed treatment 99 (87.6) 47 (85.2) 52 (88.1)
    Lost to follow-up 8 (7.1) 4 (7.4) 4 (6.8)
    Discontinued study 4 (3.5) 3 (5.6) 1 (1.7)
    Died 2 (1.8) 0 (0.0) 2 (3.4)
a

The software could not calculate weight-for-age Z score for participants who were over 10 years old.